Détail du document
Identifiant

doi:10.1186/s12866-023-03143-x...

Auteur
Motamedi, Hamid Abiri, Ramin Salari, Farhad Jalili, Cyrus Alvandi, Amirhoushang
Langue
en
Editeur

BioMed Central

Catégorie

Mycology

Année

2023

Date de référencement

20/12/2023

Mots clés
ureb caga sirna ... caga sirna ureb
Métrique

Résumé

Background Two important virulence factors, urease and cagA, play an important role in Helicobacter pylori ( H. pylori ) gastric cancer.

Aim of this study was to investigate the expression level and function of ureB and cagA using small interfering RNAs (siRNA).

Methods SS1 strain of H. pylori was considered as host for natural transformation.

siRNA designed for ureB and cagA genes were inserted in pGPU6/GFP/Neo siRNA plasmid vector to evaluate using phenotypic and genotypic approaches.

Then, qPCR was performed for determining inhibition rate of ureB and cagA gene expression.

Results The expression levels of siRNA-ureB and siRNA-cagA in the recombinant strain SS1 were reduced by about 5000 and 1000 fold, respectively, compared to the native H. pylori strain SS1.

Also, preliminary evaluation of siRNA-ureB in vitro showed inhibition of urea enzyme activity.

These data suggest that siRNA may be a powerful new tool for gene silencing in vitro, and for the development of RNAi-based anti- H. pylori therapies.

Conclusion Our results show that targeting ureB and cagA genes with siRNA seems to be a new strategy to inhibit urease enzyme activity, reduce inflammation and colonization rate.

Motamedi, Hamid,Abiri, Ramin,Salari, Farhad,Jalili, Cyrus,Alvandi, Amirhoushang, 2023, Reduction of UreB and CagA expression level by siRNA construct in Helicobacter pylori strain SS1, BioMed Central

Document

Ouvrir

Partager

Source

Articles recommandés par ES/IODE IA

Gene expression profiles in clinically T1-2N0 ER+HER2− breast cancer patients treated with breast-conserving therapy: their added value in case sentinel lymph node biopsy is not performed
breast cancer sentinel lymph node biopsy gene expression profile adjuvant chemotherapy gep treated status guideline-2020 outcome patients cancer chemotherapy breast predict